Regulation of Cancer Immune Checkpoints Molecular and Cellular Mechanisms and Therapy Introduction

被引：0
作者：
Liu, Jie [1 ,2 ]
Xu, Jie [3 ]
机构：
[1] Fudan Univ, Huashan Hosp, Dept Digest Dis, Shanghai 200040, Peoples R China
[2] Fudan Univ, Inst Biomed Sci, State Key Lab Genet Engn, Dept Immunol, Shanghai 200433, Peoples R China
[3] Fudan Univ, Zhongshan Xuhui Hosp, Inst Biomed Sci, Shanghai 200032, Peoples R China
来源：
REGULATION OF CANCER IMMUNE CHECKPOINTS: MOLECULAR AND CELLULAR MECHANISMS AND THERAPY | 2020年 / 1248卷
关键词：
Immune checkpoint; Cancer immunotherapy; Gene regulation; Biomarkers; Antibody; BLOCKADE; IMMUNOTHERAPY; PD-1;
D O I：
10.1007/978-981-15-3266-5_1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cancer immunotherapy, especially immune checkpoint blockade therapy, represents a hotspot in cancer research. However, the low response rate, adaptive/acquired resistance, and adverse effects still keep most cancer patients from obtaining sustained clinical benefits. To overcome these limitations, it is essential to improve our understanding on the regulation of immune checkpoints under physiological and pathological contexts. Recent researches have gained insights into the molecular control of immune checkpoint receptors and ligands, which extended our knowledge on the immune system and provided alternative strategies for developing checkpoint inhibitors.
引用
收藏
页码：1 / 6
页数：6
相关论文
共 18 条
[1]   Immune Checkpoint Blockade in Cancer Therapy The 2015 Lasker-DeBakey Clinical Medical Research Award [J].
Allison, James P. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (11) :1113-1114
[2]  
[Anonymous], 2018, NAT REV DRUG DISCOV
[3]   Harnessing the Immune System for the Treatment of Non-Small-Cell Lung Cancer [J].
Brahmer, Julie R. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) :1021-1028
[4]   Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies [J].
Byun, David J. ;
Wolchok, Jedd D. ;
Rosenberg, Lynne M. ;
Girotra, Monica .
NATURE REVIEWS ENDOCRINOLOGY, 2017, 13 (04) :195-207
[5]   The multiple mechanisms that regulate p53 activity and cell fate [J].
Hafner, Antonina ;
Bulyk, Martha L. ;
Jambhekar, Ashwini ;
Lahav, Galit .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2019, 20 (04) :199-210
[6]   Identification and characterization of an alternative cancer-derived PD-L1 splice variant [J].
Hassounah, Nadia B. ;
Malladi, Venkat S. ;
Huang, Yi ;
Freeman, Samuel S. ;
Beauchamp, Ellen M. ;
Koyama, Shohei ;
Souders, Nicholas ;
Martin, Sunil ;
Dranoff, Glenn ;
Wong, Kwok-Kin ;
Pedamallu, Chandra S. ;
Hammerman, Peter S. ;
Akbay, Esra A. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (03) :407-420
[7]   Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth [J].
Kleffel, Sonja ;
Posch, Christian ;
Barthel, Steven R. ;
Mueller, Hansgeorg ;
Schlapbach, Christoph ;
Guenova, Emmanuella ;
Elco, Christopher P. ;
Lee, Nayoung ;
Juneja, Vikram R. ;
Zhan, Qian ;
Lian, Christine G. ;
Thomi, Rahel ;
Hoetzenecker, Wolfram ;
Cozzio, Antonio ;
Dummer, Reinhard ;
Mihm, Martin C., Jr. ;
Flaherty, Keith T. ;
Frank, Markus H. ;
Murphy, George F. ;
Sharpe, Arlene H. ;
Kupper, Thomas S. ;
Schatton, Tobias .
CELL, 2015, 162 (06) :1242-1256
[8]   Programmed Cell Death-1 (PD-1) Checkpoint Blockade in Combination With a Mammalian Target of Rapamycin Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell-Intrinsic PD-1 [J].
Li, Hui ;
Li, Xiaoqiang ;
Liu, Shuang ;
Guo, Lei ;
Zhang, Bo ;
Zhang, Jubo ;
Ye, Qinghai .
HEPATOLOGY, 2017, 66 (06) :1920-1933
[9]   A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity [J].
Liang, Lunxi ;
Wang, Huanbin ;
Shi, Hubing ;
Li, Zhaoli ;
Yao, Han ;
Bu, Zhigao ;
Song, Ningning ;
Li, Chushu ;
Xiang, Dabin ;
Zhang, Yao ;
Wang, Jilin ;
Hu, Ye ;
Xu, Qi ;
Ma, Yanlei ;
Cheng, Zhongyi ;
Wang, Yingchao ;
Zhao, Shuliang ;
Qian, Jin ;
Chen, Yingxuan ;
Fang, Jing-Yuan ;
Xu, Jie .
CELL CHEMICAL BIOLOGY, 2018, 25 (06) :761-+
[10]   T CELL SIGNALLING p53 controls the crowd [J].
Minton, Kirsty .
NATURE REVIEWS IMMUNOLOGY, 2014, 14 (06) :358-359
12